Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

Evolution of Protein Molecules

Solid tumours are an enormous cancer burden and a major therapeutic challenge. The cancer stem cell (CSC) hypothesis provides an attractive cellular mechanism to account for the therapeutic refractoriness and dormant behaviour exhibited by many of these tumours. There is increasing evidence that diverse solid tumours are hierarchically organized and sustained by a distinct subpopulation of CSCs. Direct evidence for the CSC hypothesis has recently emerged from mouse models of epithelial tumorigenesis, although alternative models of heterogeneity also seem to apply. The clinical relevance of CSCs remains a fundamental issue but preliminary findings indicate that specific targeting may be possible.

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

Infectious Diseases Society of America.

MYC on the Path to Cancer

L'invention concerne des anticorps diriges contre l'antigene CD33 associe a des tumeurs et leur utilisation pour l'immunociblage de cellules CD33-positives. Les anticorps selon l'invention conviennent pour l'utilisation dans le domaine de la medecine, de la pharmacie et de la recherche biomedicale. Pour cela, l'invention a pour objet de nouveaux anticorps anti-CD33 qui contiennent les regions determinant la complementarite ( complementary determining regions , CDR), definies dans les revendications. Les anticorps selon l'invention se caracterisent par une affinite elevee pour CD33 humain, de l'ordre de 10 -10 mol/l. Grâce a cette affinite elevee, les sequences des CDR selon l'invention conviennent notamment a la production de fragments recombinants (tels que des fragments scFv ou des anticorps bispecifiques) et a l'immunociblage. L'invention a egalement trait a l'utilisation d'un anticorps selon l'invention pour la preparation d'un agent pharmaceutique pour l'application therapeutique et/ou diagnostique dans le cadre de troubles associes a l'expression de CD33, notamment dans le cadre de la leucemie myeloide aigue (LMA). L'invention concerne aussi une composition pharmaceutique qui contient un ou plusieurs anticorps selon l'invention en association avec un diluant ou un support pharmaceutiquement acceptable.

Anticorps anti-cd33 et leur utilisation pour l'immunociblage dans le cadre du traitement de troubles associés à cd33

In Vivo Analysis of Heterogeneous Extracellular Vesicles Using a Red-Shifted Bioluminescence Resonance Energy Transfer Reporter Protein.

Calcium is pivotally involved in many biochemical processes in different cell types. This divalent cation mediates its function by interacting with specific calcium binding proteins that serve as calcium sensors and regulatory proteins. In our earlier studies we found that calcium was involved in the protein-protein interaction observed between Ro 60 multiple antigenic peptides (MAPs) and Ro 60 autoantigen. Since calcium was found to bind Ro 60 MAPs we hypothesized that it would renature human recombinant Ro 60 on a protein blot. As hypothesized antibodies to Ro 60 bound significantly higher to the recombinant Ro antigen that was incubated with calcium compared with that incubated without calcium on a polyvinyline fluoride (PVDF) blot. Since the immmunological epitopes of Ro 60 are mainly conformational, we believe that calcium induced a more native tertiary structure in recombinant Ro 60 autoantigen -following blotting to a PVDF membrane.

Michael Bachmann

Papers

Anticorps anti-cd33 et leur utilisation pour l'immunociblage dans le cadre du traitement de troubles associés à cd33

In Vivo Analysis of Heterogeneous Extracellular Vesicles Using a Red-Shifted Bioluminescence Resonance Energy Transfer Reporter Protein.

Renaturation of recombinant Ro 60 autoantigen by calcium ions on PVDF membrane.

Roll-back stop method and device for a motor vehicle

The sigma-1 receptor: Potential role in the modulation of cellular radiation sensitivity